- Home
- CLVT vs SVRA Comparison
CLVT vs SVRA Comparison
Compare CLVT & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLVT | SVRA |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United Kingdom | United States |
| Employees | 12000 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | CLVT | SVRA |
|---|---|---|
| Price | $1.96 | $5.37 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $3.22 | ★ $7.33 |
| AVG Volume (30 Days) | ★ 7.3M | 1.8M |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.12 | $430.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.66 | $2.43 |
| 52 Week High | $4.56 | $7.01 |
Technical Indicators
Market Signals| Indicator | CLVT | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 41.78 | 43.55 |
| Support Level | $1.66 | $4.77 |
| Resistance Level | $2.65 | $5.43 |
| Average True Range (ATR) | 0.19 | 0.29 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 28.30 | 24.26 |
Price Performance
Historical ComparisonAbout CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).